IE stock · Healthcare sector · Medical Devices
Company Logo

Medtronic plc

MDTNYSE

80.75

USD
-1.52
(-1.85%)
Market Closed
21.48P/E
14Forward P/E
1.07P/E to S&P500
107.329BMarket CAP
3.12%Div Yield
Upcoming Earnings
22 Nov
Shares Short
9/15/22
7.92M
Short % of Float
0.60%
Short % of Shares Outs.
0.60%
% Held by Insiders
0.14%
% Held by Institutions
83.41%
Beta
0.76
PEG Ratio
1.41
52w. high/low
128.85/80.39
Avg. Daily Volume
5.51M
Return %
Stock
S&P 500
1 year
(35.04)
(16.20)
3 years
(24.01)
22.35
5 years
5.77
44.82
Scale: |
High
Low
57.99
44.87
56.97
28.33
44.94
24.06
46.66
30.80
43.33
30.18
44.79
35.67
58.85
41.16
75.66
53.33
79.50
55.54
89.27
71.03
89.72
69.35
100.15
76.41
115.94
81.66
122.15
72.13
135.89
98.38
114.31
80.39
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
Revenue per share
10.70
11.95
13.06
14.30
14.79
15.36
16.28
16.97
18.49
20.45
21.55
22.08
22.70
21.57
22.39
23.60
23.20
Earnings per share
2.44
1.97
1.94
2.80
2.87
3.43
3.40
3.06
2.44
2.51
2.92
2.29
3.44
3.57
2.68
3.75
3.88
FCF per share
1.99
2.55
2.88
3.16
2.96
3.77
4.34
4.55
3.95
2.96
4.08
2.67
4.36
4.49
3.63
4.45
4.27
Dividends per share
0.44
0.50
0.75
0.82
0.90
0.97
1.04
1.11
1.22
1.52
1.72
1.84
2.00
2.16
2.32
2.52
2.57
CAPEX per share
0.60
0.54
0.59
0.57
0.51
0.47
0.45
0.40
0.52
0.74
0.91
0.79
0.84
0.90
1.01
1.02
1.06
Book Value per sh.
9.55
10.20
11.50
13.22
14.82
16.24
18.32
19.40
48.59
36.93
36.47
37.38
37.20
37.84
38.24
39.15
39.16
Comm.Shares outs.
1,150
1,131
1,118
1,106
1,077
1,054
1,019
1,002
1,096
1,410
1,379
1,357
1,346
1,341
1,345
1,342
1,339
Avg. annual P/E ratio
21.2
23.7
18.0
13.9
12.9
11.6
15.1
20.6
30.4
31.9
27.8
38.4
28.7
28.6
45.3
26.3
21.5
P/E to S&P500
1.2
1.1
0.3
0.7
0.8
0.8
0.9
1.1
1.5
1.4
1.2
1.5
1.2
0.8
1.5
1.3
1.1
Avg. annual div. yield
0.8%
1.1%
2.2%
2.1%
2.4%
2.4%
2.0%
1.8%
1.6%
1.9%
2.1%
2.1%
2.0%
2.1%
1.9%
2.6%
2.5%
Revenue (m)
12,299
13,515
14,599
15,817
15,933
16,184
16,590
17,005
20,261
28,833
29,710
29,953
30,557
28,913
30,117
31,686
31,070
Operating margin
30.4%
30.2%
28.6%
27.1%
28.4%
29.9%
28.8%
28.3%
18.6%
18.4%
17.9%
22.2%
20.5%
16.6%
14.9%
18.2%
19.3%
Depreciation (m)
583
637
699
772
804
833
819
850
1,306
2,820
2,917
2,644
2,659
2,663
2,702
2,707
2,704
Net profit (m)
2,802
2,231
2,169
3,099
3,096
3,617
3,467
3,065
2,675
3,538
4,028
3,104
4,631
4,789
3,606
5,039
5,205
Income tax rate
20.3%
22.7%
16.4%
21.9%
16.8%
17.6%
18.4%
17.3%
23.3%
18.4%
12.6%
45.5%
10.5%
(17.0)%
6.8%
8.3%
9.0%
Net profit margin
22.8%
16.5%
14.9%
19.6%
19.4%
22.3%
20.9%
18.0%
13.2%
12.3%
13.6%
10.4%
15.2%
16.6%
12.0%
15.9%
16.7%
Working capital (m)
5,355
3,787
4,313
4,718
4,403
3,658
13,902
15,651
21,671
16,435
10,609
12,896
13,495
11,665
14,039
10,665
8,086
Long-term debt (m)
5,578
5,802
6,772
6,944
8,112
7,359
9,408
10,120
33,752
30,109
25,921
23,699
24,486
22,021
26,378
20,372
17,481
Equity (m)
10,977
11,536
12,851
14,629
15,968
17,113
18,671
19,443
53,230
52,063
50,294
50,720
50,091
50,737
51,428
52,551
52,672
ROIC
16.5%
12.0%
11.5%
14.9%
13.5%
14.2%
12.2%
10.4%
3.3%
5.0%
5.8%
4.6%
7.3%
7.6%
5.3%
7.1%
7.6%
Return on capital
18.0%
13.0%
11.9%
15.6%
13.7%
14.2%
13.3%
10.8%
3.9%
5.7%
5.7%
7.5%
7.4%
5.7%
5.2%
6.7%
7.0%
Return on equity
25.5%
19.3%
16.9%
21.2%
19.4%
21.1%
18.6%
15.8%
5.0%
6.8%
8.0%
6.1%
9.2%
9.4%
7.0%
9.6%
9.9%
Plowback ratio
82.0%
74.7%
61.1%
70.7%
68.7%
71.8%
69.6%
63.6%
50.0%
39.5%
41.0%
19.7%
41.8%
39.6%
13.5%
32.9%
33.9%
Div.&Repurch./FCF
53.0%
59.2%
36.9%
50.7%
63.4%
59.6%
46.0%
51.8%
60.2%
107.3%
97.6%
117.9%
77.9%
59.1%
67.5%
92.0%
93.5%
Capital Structure
1 Sep · 2022 | Q1
All numbers in millions
Total liabilities
$ 37,071
Total assets
$ 89,914
Long-term debt
$ 17,481
Cash and equiv.
$ 2,140
Goodwill
$ 40,324
Retained earnings
$ 30,276
Common stock
1,329
Enterprise Value
$ 122,670
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
10,948
10,817
10,573
Receivables
4,645
5,462
5,551
Inventory
4,229
4,313
4,616
Other
2,209
1,409
1,893
Current assets
22,031
22,548
23,059
Acc. Payable
1,996
2,106
2,276
Debt due
2,776
11
3,742
Other
5,594
6,392
6,376
Current liabilities
10,366
8,509
12,394
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
5.21%
1.50%
8.20%
Cash flow
22.37%
17.11%
6.88%
Earnings
39.74%
16.91%
7.39%
Dividends
8.43%
7.92%
14.81%
Book value
2.18%
0.90%
19.64%
Insider Trading
Type
Shares
Date
Wall Brett A.
Award
59,433
08/01/22
Wall Brett A.
Award
18,802
08/01/22
Wall Brett A.
Award
7,521
08/01/22
Smith Gregory L
Award
44,151
08/01/22
Smith Gregory L
Award
13,967
08/01/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2021
6,507
7,647
7,775
8,188
30,117
2022
7,987
7,847
7,763
8,089
31,686
2023
7,371
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
0.36
0.37
0.94
1.01
2.68
2022
0.57
0.98
1.10
1.11
3.75
2023
0.70
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
0.58
0.58
0.58
0.58
2.32
2022
0.63
0.63
0.63
0.63
2.52
2023
0.68
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Medical Devices
CEO:
Mr. Omar Ishrak
Full-time employees:
95,000
City:
DUBLIN
Address:
20 On Hatch, Hatch Street Lower
IPO:
Mar 17, 1980
Website:
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.